The present invention provides a compound of formula (I): wherein R.sup.1-R.sup.5, R.sup.25, R.sup.26, Y, y, and X.sup.2 are as defined herein. The compounds activate human peroxisome proliferater activated receptors (hPPARs) and are useful for the treatment of associated disorders such as dyslipidemia, syndrome X, hypercholesteremia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, and obesity.